William Blair Downgrades Aclaris Therapeutics to Market Perform
Portfolio Pulse from Benzinga Newsdesk
William Blair analyst Tim Lugo has downgraded Aclaris Therapeutics (NASDAQ:ACRS) from Outperform to Market Perform, indicating a change in the firm's outlook on the company's stock performance.
November 13, 2023 | 4:55 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Aclaris Therapeutics was downgraded by William Blair from Outperform to Market Perform, which may influence investors' perception of the stock.
Downgrades by analysts can lead to a negative short-term reaction in the stock market as they may reflect a less optimistic outlook on the company's future performance. Investors often consider such ratings changes when making decisions.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100